U Sports Football Athlete Reprimanded for Presence of Salbutamol
(Ottawa, Ontario – December 21, 2016) – The Canadian Centre for Ethics in Sport (CCES) announced today that Charles-William Tremblay, a U Sports football player from McGill University, has committed an anti-doping rule violation and has received a sanction of a reprimand. The athlete’s urine sample, collected during out-of-competition doping control on May 12, 2016, revealed the presence of salbutamol in excess of the threshold stated in the World Anti-Doping Agency Prohibited List.
The presence of salbutamol, classified as a “specified substance” on the Prohibited List, is considered an adverse analytical finding when the urinary concentration exceeds 1,000ng/mL. Under the rules of the Canadian Anti-Doping Program (CADP), an athlete facing a first violation involving a “specified substance” can seek to have the sanction reduced. Based on factors assessed, including the athlete's degree of fault, the CCES proposed a sanction of a reprimand and no period of ineligibility.
In response to the CCES’ notification of the adverse analytical finding, Mr. Tremblay waived his right to a hearing, acknowledged the anti-doping rule violation and accepted the sanction of a reprimand proposed by the CCES.
In compliance with rule 7.10 of the CADP, a copy of the CCES’ file outcome summary can be found at http://cces.ca/sites/default/files/content/docs/pdf/file-outcome-summary-tremblay-e.pdf.
The CCES is an independent, national, not-for profit organization with a responsibility to administer the CADP. Under the CADP rules, the CCES announces publicly every anti-doping rule violation. We recognize that true sport can make a great difference for individuals, communities and our country. We are committed to working collaboratively to activate a values-based and principle-driven sport system; protecting the integrity of sport from the negative forces of doping and other unethical threats; and advocating for sport that is fair, safe and open to everyone.
-- 30 --
For further information, please contact:
+1 613-521-3340 x3314